Martina E Spehlmann
Affiliation: Campus Kiel
- Epidemiology of inflammatory bowel disease in a German twin cohort: results of a nationwide studyMartina E Spehlmann
Institute for Clinical Molecular Biology, University Schleswig Holstein, Kiel, Germany
Inflamm Bowel Dis 14:968-76. 2008..The aim of our study was to determine the concordance rates for IBD in German twin pairs and to evaluate clinical characteristics of concordant and discordant twin pairs...
- Risk factors in German twins with inflammatory bowel disease: results of a questionnaire-based surveyMartina E Spehlmann
Clinic of General Internal Medicine, University Hospital Schleswig Holstein, Campus Kiel, Schittenhelmstrasse 12, 24105 Kiel, Germany
J Crohns Colitis 6:29-42. 2012..Environmental factors may play an important role in the pathogenesis of IBD. The history of patients of the German IBD twin study was analyzed by questionnaires and interviews...
- Whole genome and exome sequencing of monozygotic twins discordant for Crohn's diseaseBritt Sabina Petersen
Institute of Clinical Molecular Biology, Christian Albrechts University of Kiel, Schittenhelmstrasse 12, 24105 Kiel, Germany
BMC Genomics 15:564. 2014..Recent studies have demonstrated genetic differences between monozygotic twins, who were long thought to be genetically completely identical...
- Twin study indicates loss of interaction between microbiota and mucosa of patients with ulcerative colitisPatricia Lepage
Institute of Clinical Molecular Biology, Christian Albrechts University Kiel, Kiel, Germany
Gastroenterology 141:227-36. 2011..We analyzed the interaction between gastrointestinal mucosal microbiota and host genes in twin pairs discordant for ulcerative colitis (UC) to study the functional interaction between microbiota and mucosal epithelium...
- Natalizumab for the treatment of active Crohn's disease: results of the ENCORE TrialStephan R Targan
Inflammatory Bowel Disease Center and Division of Gastroenterology, Cedars Sinai Medical Center, Los Angeles, California 90048, USA
Gastroenterology 132:1672-83. 2007..A randomized placebo-controlled trial evaluated the efficacy of natalizumab induction therapy in patients with Crohn's disease...